Medicare Reform Reshapes Drug Pricing and Insurance Markets for 2026
Federal policy shifts including a $2,100 drug cost cap and new obesity medication subsidies are forcing insurers and pharmaceutical giants to overhaul their business models.
Federal policy shifts including a $2,100 drug cost cap and new obesity medication subsidies are forcing insurers and pharmaceutical giants to overhaul their business models.
New FDA approvals for surgical software and the formation of rural hospital networks highlight a national push to balance high-tech innovation with fiscal sustainability.
Federal regulators have imposed a nationwide moratorium on new hospice and home health Medicare enrollments to protect program solvency and stop systemic billing abuse.
Federal investigators report that major Medicare Advantage plans are systematically denying post-acute rehabilitation care, with many decisions later overturned upon appeal.
Researchers have identified a potent anti-cancer compound, Salinosporamide A, derived from the deep-sea bacterium Salinispora tropica. Clinical trials at major medical centers are currently evaluating its efficacy in treating glioblastoma,…
Regulatory failures in India and a spike in U.S. supplement poisonings underscore the urgent need for manufacturing accountability and evidence-based medical guidance in an era of misinformation.
Regeneron Pharmaceuticals has demonstrated that its gene therapy, DB-OTO, can restore hearing in children born with profound deafness due to OTOF gene mutations. The therapy uses a dual-vector viral system…
New injectable hydrogels promising cartilage repair for osteoarthritis patients face a complex path through FDA classification and Medicare's evolving 2026 pricing and reimbursement frameworks.
A collaborative study between Roche and Harvard University has led to the discovery of Zosurabalpin, a new antibiotic class that effectively kills carbapenem-resistant Acinetobacter baumannii. The drug works by inhibiting…